MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s13045-021-01221-z

Медицинская библиотека · Journal of hematology & oncology · 2022

Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee.

Januzzi James L, Garasic Joseph M, Kasner Scott E, McDonald Vickie, Petrie Mark C, Seltzer Jonathan, Mauro Michael, Croce Kevin, Berman Ellin, Deininger Michael, Hochhaus Andreas, Pinilla-Ibarz Javier, Nicolini Franck, Kim Dong-Wook, DeAngelo Daniel J, Kantarjian Hagop, Xu Jing, Hall Tracey, Srivastava Shouryadeep, Naranjo Daniel, Cortes Jorge

Клиническое исследование II фазыСтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

The phase 2 PACE (Ponatinib Ph+ ALL and CML Evaluation) trial of ponatinib showed robust long-term benefit in relapsed Philadelphia chromosome-positive (Ph+) leukemia; arterial occlusive events (AOEs) occurred in ≥ 25% of patients based on investigator reporting. However, AOE rates vary depending on the definitions and reporting approach used.

METHODS

To better understand clinically relevant AOEs with ponatinib, an independent cardiovascular adjudication committee reviewed 5-year AOE data from the PACE trial according to a charter-defined process and standardized event definitions.

RESULTS

A total of 449 patients with chronic myeloid leukemia (CML) or Ph+ acute lymphoblastic leukemia (ALL) received ponatinib (median age 59 y; 47% female; 93% ≥ 2 prior tyrosine kinase inhibitors (TKIs); median follow-up, 37.3 months). The adjudicated AOE rate (17%) was lower than the non-adjudicated rate (i.e., rate before adjudication; 25%). The only adjudicated AOE in > 2% of patients was peripheral arterial occlusive disease (4%). Exposure-adjusted incidence of newly occurring adjudicated AOEs decreased over time. Patients with multiple baseline cardiovascular risk factors had higher adjudicated AOE rates than those without risk factors.

CONCLUSIONS

This independent adjudication study identified lower AOE rates than previously reported, suggesting earlier overestimation that may inaccurately reflect AOE risk with ponatinib. This trial was registered under ClinicalTrials.gov identifier NCT01207440 on September 23, 2010 ( https://clinicaltrials.gov/ct2/show/NCT01207440 ).

Для цитирования: Januzzi James L, Garasic Joseph M, Kasner Scott E, McDonald Vickie, Petrie Mark C, Seltzer Jonathan, Mauro Michael, Croce Kevin, Berman Ellin, Deininger Michael, Hochhaus Andreas, Pinilla-Ibarz Javier, Nicolini Franck, Kim Dong-Wook, DeAngelo Daniel J, Kantarjian Hagop, Xu Jing, Hall Tracey, Srivastava Shouryadeep, Naranjo Daniel, Cortes Jorge. Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee.. Journal of hematology & oncology. 2022. DOI: 10.1186/s13045-021-01221-z.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.